GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...

GlaxoSmithKline has announced more data making the case for its multiple myeloma antibody-drug conjugate GSK2857916, confirming that almost two thirds of patients responded to the drug after an ...

A: Avastin; Ag: Antigen; mAb: Monoclonal antibody; MM: Multiple myeloma ... conjugates are a novel strategy aiming to minimize side effects of chemotherapy and specifically deliver cytotoxic drugs ...

GSK has announced positive headline outcomes from a Phase III trial of Blenrep with bortezomib and dexamethasone for multiple ...

The Orphan Drug designation was supported by preclinical research and preliminary data from the dose escalation/expansion phase 1/2 trial.

GSK reported positive results from its phase three ‘DREAMM-7’ trial on Thursday, highlighting a significant overall survival ...

As pharmaceutical companies embrace antibody-drug conjugates (ADCs) as a way to treat cancer, drug services providers are ...

LONDON, UK I 14, 2024 I GSK plc (LSE/NYSE: GSK) today announced positive headline results from a planned interim analysis of the DREAMM-7 ...

But over time, the disease is able to change and become resistant to the drugs most often used to fight it. When multiple myeloma comes back after treatment, that’s called a relapse. When ...

Following the clearance of an investigational new drug application from the FDA, a phase 1 trial will examine the novel ...

The FDA has granted LBL-034 orphan drug designation for relapsed/refractory multiple myeloma treatment. LBL-034 has received ...